| Catalog No. | HB651016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4 |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P16410 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | BMS-734016, MDX-010, MDX-CTLA-4, 477202-00-9 |
|---|
| Background | HY-P990945 is an CTLA4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870
• CTLA-4: a moving target in immunotherapy., PMID:29118008
• CTLA-4: From mechanism to autoimmune therapy., PMID:32007707
• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845
• Immune-related adverse events with immune checkpoint blockade: a comprehensive review., PMID:26765102
• Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy., PMID:27079802
• CD28 Costimulation: From Mechanism to Therapy., PMID:27192564
• Association Between., PMID:35271496
• Immune checkpoint inhibitors., PMID:30760493
• Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer., PMID:38956700
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
